Technical Analysis for TLSA - Tiziana Life Sciences plc

Grade Last Price % Change Price Change
grade D 6.3238 -6.43% -0.43
TLSA closed down 6.43 percent on Thursday, September 19, 2019, on 1.19 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A Down Down
See historical TLSA trend table...

Date Alert Name Type % Chg
MACD Bearish Centerline Cross Bearish 0.00%
Stochastic Reached Oversold Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
MACD Bearish Signal Line Cross Bearish -6.43%
Calm After Storm Range Contraction -6.43%
Down 3 Days in a Row Weakness -6.43%
Fell Below 20 DMA Bearish -9.01%
Fell Below 50 DMA Bearish -9.01%

Older signals for TLSA ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Tiziana Life Sciences PLC develops novel molecules that impact serious human diseases in oncology and immunology. It is focused on developing next-generation therapeutics and diagnostics for cancers and immune diseases.
Cancer Immunology Cancers Immune Diseases
Is TLSA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Sep 16 Tiziana Life Sciences Announces FDA Approval to Initiate Phase I Clinical Trial with Orally Administered Foralumab in Healthy Volunteers
Sep 10 Tiziana Reports Phase 1 Clinical Data Demonstrating Nasal Treatment with Foralumab was Well-tolerated and Produced Positive Trend in Biomarkers of Immunomodulation and Anti-inflammation in Healthy Volunteers
Sep 4 Tiziana Life Sciences Reports Positive Phase 2a Clinical Data Exhibiting Positive Clinical Activity with Milciclib Monotherapy in Advanced Sorafenib-refractory or -intolerant Patients with Unresectable or Metastatic Hepatocellular Carcinoma
Jul 22 Tiziana Reports Phase 2a Clinical Data with Milciclib Monotherapy in Sorafenib-refractory or -intolerant patients with unresectable or metastatic Hepatocellular Carcinoma
Jul 1 Tiziana Life Science reports Independent Third Party Article in New England Journal of Medicine on Intravenous Treatment with a Humanized Anti-CD3 mAb showing delays in progression of Type 1 Diabetes
Jun 24 Newly Published Article Reporting Clinical Activity of Orally Administered OKT3, a Mouse Anti-CD3 Monoclonal Antibody, in Moderate to Severe Ulcerative Colitis Patients, Supports Tiziana’s Oral Monoclonal Antibody Platform
Jun 5 Tiziana Life Sciences Shares Resume Trade, Up 12% For Session
May 28 Tiziana Life Sciences to Present at the 9th Annual LD Micro Invitational
May 18 Stocks To Watch: Retail On Display
May 1 Tesla Continues To Ask The Right Questions, Design Good Strategy, But Questions Remain On Execution
See more TLSA news...
Indicator Value
52 Week High 12.17
52 Week Low 5.0
Average Volume 4,783
200-Day Moving Average 0.0
50-Day Moving Average 7.0342
20-Day Moving Average 6.9727
10-Day Moving Average 7.1322
Average True Range 0.6264
ADX 21.82
+DI 27.6115
-DI 22.1348
Chandelier Exit (Long, 3 ATRs ) 7.150799999999999
Chandelier Exit (Short, 3 ATRs ) 7.9992
Upper Bollinger Band 7.9667
Lower Bollinger Band 5.9787
Percent B (%b) 0.17
BandWidth 28.511194
MACD Line -0.0592
MACD Signal Line 0.0058
MACD Histogram -0.0651
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.23
Resistance 3 (R3) 7.26 7.00 7.08
Resistance 2 (R2) 7.00 6.77 6.98 7.03
Resistance 1 (R1) 6.66 6.63 6.53 6.63 6.98
Pivot Point 6.40 6.40 6.33 6.38 6.40
Support 1 (S1) 6.06 6.17 5.93 6.02 5.67
Support 2 (S2) 5.79 6.02 5.77 5.62
Support 3 (S3) 5.45 5.79 5.57
Support 4 (S4) 5.42